Bio-Rad Laboratories Inc Class A
BIO: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$924.00 | Tnwb | Wgnzcmyw |
Bio-Rad's Life Sciences Unit Benefiting From Pandemic, but Diagnostics Facing Headwinds
Business Strategy and Outlook
Bio-Rad develops products and solutions for the life science research and clinical diagnostic markets and has niche market leadership in diagnostic quality controls, antigens, and digital polymerase chain reaction, or PCR, molecular testing. Bio-Rad’s business relies on the razor/razor blade model typically seen in the diagnostic market, and consumable reagents account for approximately 65% of total sales, with these reagents generally sold at a higher margin than their associated equipment and instruments.